Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
Clinical trial NCT05399329 · COMPLETED
Trial details
- NCT number
- NCT05399329
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-04-20
- Primary completion
- 2025-06-27
- Enrollment
- 693
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.